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HIGH USERS OF 2-AGONISTS: ARE MEDICAID 
RECIPIENTS BEING TREATED ACCORDING TO 
NATIONAL ASTHMA GUIDELINES?
Reddy P1, Kelly E1, Kophazi M2, Geary E3, Markelon J1, 
Welter K1
1Pharmacy School, University of Connecticut, Storrs, CT, USA; 
2Health Information Design Inc., Auburn, AL, USA; 
3Connecticut Medicaid Department, Hartford, CT, USA
Studies have shown an association between increased use
of 2-agonists and risk of death. Little information is
available on the appropriateness of asthma management
in Medicaid populations although data suggest that Med-
icaid recipients experience higher healthcare utilization
than non-Medicaid recipients. OBJECTIVE: To deter-
mine whether Medicaid’s high dose 2-agonists (HDB)
users (1 inhaler/month) are being managed according
to National Institute of Health (NIH) asthma guidelines.
METHODS: All Connecticut Medicaid pharmacy claims
from April to December 1998 were examined. Subjects
were included if they had an asthma diagnosis and were
5 years old. Subjects were excluded if they had chronic
obstructive airway disease or a claim for ipratropium.
The percent of HDB users receiving (1) no long-term con-
troller (LTC  inhaled corticosteroid, theophylline, leu-
kotriene modifier, mast cell stabilizer); (2) low doses of a
LTC; (3) oral or nebulized 2-agonists; (4) spacers or
peak flow meters was determined. RESULTS: A total of
1596 profiles were included (42  16 years, mean 
SD;79% female); 178 were excluded. Fourteen percent
were HDB users; of these 24% did not have a claim for a
LTC and 29% received low doses of a LTC. Oral or neb-
ulized 2-agonists claims were submitted by 34% of HDB
users. Seven percent and 0% of HDB users submitted
claims for spacers and peak flow meters, respectively.
CONCLUSION: A high proportion of Medicaid asthma
patients who are HDB users are not being managed ac-
cording to recent NIH guidelines. Intervention programs
designed to improve adherence to the guidelines will be
developed.
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IDENTIFYING FACTORS ASSOCIATED WITH 
HIGH AND LOW COST ASTHMATICS: 
OPPORTUNITIES FOR DISEASE MANAGEMENT 
USING AUTOMATIC 
INTERACTION DETECTION
Boscarino JA, Zhao Z, Andrews KW, Sokol MC, Yao J, 
McGuigan KA, Gutierrez B, Refowitz, R
Merck-Medco Managed Care, Franklin Lakes, NJ, USA
Because the costs of treating asthmatic patients vary, we
wanted to develop cost-effective health management strat-
egies by identifying factors associated with high and low
cost patients. METHODS: We integrated 24 months of
medical and drug claims data for 89,245 individuals who
had health benefits through two large US companies. In-
dividuals were defined as asthmatics if they had two or
more asthma medical or asthma drug claims over the first
12 months. 1,529 asthmatics (mean age  38; females 
56%) were included in our study, after excluding those
under age 5, over age 64, and COPD cases. We predicted
costs in the second year based on first-year risk factors,
using a recursive partitioning, Chi-squared Automatic In-
teraction Detection (CHAID) model. Predictor variables
included: age, gender, region, member status, and 18 co-
morbidities based on the ICD-9 body-system method.
RESULTS: We found higher average costs associated
with asthmatics that had either circulatory disorders
($6,796, P  0.0001) or cancers ($6,381, P  0.009).
However, asthmatics with circulatory and mental disor-
ders ($20,035, P  0.0001), digestive and nervous sys-
tem disorders ($12,447, P  0.008), and those with cir-
culatory and nervous system disorders ($11,633, P 
0.0001) had the highest average costs. Conversely, the
lowest costs were associated with 6–39 year old, male
($691, P  0.03) and female ($1331, P  0.05) asthmat-
ics without comorbidities. The R2 for the CHAID model
was similar to stepwise regression (both approximately
12% for actual dollars and 30% for log dollars), and
most of the variables selected were the same. CONCLU-
SIONS: Our analysis identified high and low cost asth-
matic patients and may be useful in guiding future inter-
ventions. In order to reduce health care costs, for
example, our study suggests asthmatics with concurrent
circulatory and mental health disorders may warrant in-
tense interventions, while younger male asthmatics with-
out comorbidities may not.
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THE NUMBER NEEDED TO TREAT APPROACH: 
EVALUATING THE CLINICAL RELEVANCE OF 
FEXOFENADINE IN SEASONAL 
ALLERGIC RHINITIS
Crawford B1, Marquis P2, Offord S3
1MAPI Values, Boston, MA, USA; 2MAPI Values, Lyon, France; 
3Aventis Pharmaceuticals, Inc, Bridgewater, NJ, USA
The use of minimal important difference (MID) in quality
of life assessment has grown recently in an effort to make
measured changes more meaningful to the practicing
physician. The use of MID, however, does not take into
account the distribution of response, only the mean. OB-
JECTIVE: To examine the use of number needed to treat
(NNT) in seasonal allergic rhinitis as a valid and more
relevant approach to present data from clinical trials to
physicians. METHODS: 538 subjects completed the Rhi-
noconjunctivitis Quality of Life Questionnaire (RQLQ),
a symptom questionnaire, and a self-reported change
scale. These data were used to determine meaningful
changes in the RQLQ and generate a 3  3 table to cal-
culate the NNT. RESULTS: We examined data from the
STAR study comparing fexofenadine, loratadine and pla-
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cebo. The endpoint change in the RQLQ was stratified
by self-assessed change to determine the NNT. This re-
sulted in a NNT of 7.9 for fexofenadine, 63.5 for lorata-
dine and 9.2 for fexofenadine versus loratadine. Thus,
between 7–8 patients require treatment with fexofena-
dine for a patient to have a clinically meaningful im-
provement in quality of life while between 63–64 patients
need to be treated with loratadine in order for one pa-
tient to obtain a significant improvement. Additional
stratifications were examined to assess the effects of im-
portant differences on the NNT. Single digit NNT values,
as seen with fexofenadine, strongly support the clinical
relevance of the drug for improving patient quality of
life. CONCLUSIONS: The NNT approach represents an
understandable approach to presenting quality of life
data that may be more meaningful to practicing physi-
cians.
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RELIABILITY AND VALIDITY OF 
INTERNATIONAL PROSTATE SYMPTOM SCORE 
(I-PSS) FOR EARLY ASSESSMENT OF SYMPTOMS 
IN THE TREATMENT OF BENIGN PROSTATE 
HYPERPLASIA (BPH)
Singh A, Ashraf T, Verlinden MH
Abbott Laboratories, Abbott Park, IL, USA
The American Urology Association has developed a 7-
item instrument I-PSS to measure the signs and symptoms
of the disease process of BPH. The instrument was vali-
dated for a one-month and later for a weekly recall. Early
and faster relief of symptoms are extremely important to
patients. Therefore, we validated I-PSS for as early as 2 to
5 day response. OBJECTIVE: To test the reliability and
validity of I-PSS administered between day two to five
post-treatment. METHODS: I-PSS was administered at
baseline and at day 2–5 after treatment as part of a double-
blind study with 674 symptomatic BPH subjects. The pa-
tients were also administered a single item global question
about their urinary condition. The test-retest reliability of
the 2–5 day version was evaluated with intra-class correla-
tion coefficient (ICC) between the two assessments. Inter-
nal consistency was computed with Cronbach’s . Guyatt’s
responsiveness statistics was estimated. Factor content of
day 2 to 5 I-PSS was examined. The ability of I-PSS
scores at days 2–5 to discriminate between improved and
unimproved subjects was tested with receiver’s operating
characteristics curve (ROC) analysis. RESULTS: The av-
Loratadine
Fexofenadine
Improved Unchanged Deteriorated
Improved 0.6089 0.0915 0.0279
Unchanged 0.1691 0.0254 0.0077
Deteriorated 0.0580 0.0087 0.0027
erage measure of ICC was found to be 0.7414. Cron-
bach’s  was estimated to be 0.8093 (Barry et al 1995 re-
ported 0.74 for ICC and 0.67 for Cronbach’s  for one-
week I-PSS). The Guyatt’s responsiveness statistic was
found to be 1.04 compared to 0.82 for a one-week
version. Factor analysis revealed only one underlying fac-
tor (urinary symptoms) with an eigenvalue greater than
one. The areas under ROC curve was 0.7635 (0.74 re-
ported for a one-week version). CONCLUSIONS: The
results conclude that I-PSS can be used to evaluate days
2–5 symptoms for BPH.
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A FRAMEWORK FOR COST-EFFECTIVENESS 
ANALYSIS FROM CLINICAL TRIAL DATA
O’Hagan A1, Stevens JW2
1University of Sheffield, Sheffield, UK; 2AstraZeneca R&D 
Charnwood, Loughborough, UK
OBJECTIVES: The research objective was to develop a
flexible Bayesian statistical framework for cost-effective-
ness analysis using data from a clinical trial, and to illus-
trate the methodology in practical case studies. METH-
ODS: The general methods of Bayesian statistical theory
are used to develop the framework. For computation of
results in case studies, simulation-based methods are
used, including Markov chain Monte Carlo. RESULTS:
A general framework is established, in which individual
patient data arising in a clinical trial may be modeled us-
ing any appropriate probability models. Within the model,
the true patient mean efficacy and true patient mean cost
are represented as functions of the model parameters.
Cost-effectiveness decisions are then based on inference
about these true mean parameters for each of the two
treatments under comparison in the trial. It is argued that
appropriate decision indicators are whether the expected
net benefit is positive, or the probability that net benefit
is positive, with net benefit defined with reference to a
specific threshold unit cost. When a range of unit costs
must be considered, the relevant indicators are the break-
even unit cost for expected net benefit, or the C/E accept-
ability curve (CEAC). Inference about these indicators is
determined within the Bayesian statistical paradigm. Ex-
amples and case studies are presented illustrating the
method with efficacy outcomes that are continuous, bi-
nary, ordinal or time-to-event, and with costs modeled as
distributed normally, lognormally or nonparametrically.
CONCLUSIONS: The Bayesian framework is demonstrated
to be both a flexible and powerful tool for cost-effectiveness
analysis from clinical trial data.
